These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 30174832)

  • 1. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to osimertinib.
    Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
    J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
    Wu L; Ke L; Zhang Z; Yu J; Meng X
    Front Oncol; 2020; 10():602762. PubMed ID: 33392095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating
    Mazza V; Cappuzzo F
    Appl Clin Genet; 2017; 10():49-56. PubMed ID: 28794650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib.
    Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
    Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
    Doval DC; Desai CJ; Sahoo TP
    Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
    Mountzios G
    Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turning
    Hirsh V
    Ther Adv Med Oncol; 2018; 10():1758834017753338. PubMed ID: 29383041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
    Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
    Front Oncol; 2022; 12():863666. PubMed ID: 35785185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
    Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
    Front Oncol; 2021; 11():621992. PubMed ID: 33718183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.